• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

The Role of 4-(4-(Trifluoromethoxy)Phenoxy)Benzoic Acid (CAS No. 617245-31-5) in Modern Chemical and Pharmaceutical Research

4-(4-(Trifluoromethoxy)Phenoxy)Benzoic Acid, identified by the CAS registry number 617245-31-5, is a synthetic organic compound with a distinctive aromatic structure that has garnered significant attention in recent years due to its potential applications in drug discovery and advanced materials science. This compound belongs to the broader category of benzoic acid derivatives, characterized by the substitution of a trifluoromethoxy (OCF?) group at the para-position of a phenyl ring, which is further linked via an ether bond to another phenolic group attached to the carboxylic acid core. The trifluoromethoxy moiety imparts unique physicochemical properties, including enhanced metabolic stability and lipophilicity, making it a valuable scaffold for designing bioactive molecules.

Recent studies have highlighted the importance of trifluoromethoxy groups in modulating pharmacokinetic profiles and improving selectivity for biological targets. For instance, a 2023 publication in Journal of Medicinal Chemistry demonstrated that incorporating such groups into benzene-based frameworks can significantly enhance binding affinity toward G-protein coupled receptors (GPCRs), a major drug target class. In the context of 4-(4-(Trifluoromethoxy)Phenoxy)Benzoic Acid, this structural feature contributes to its ability to traverse cellular membranes while resisting enzymatic degradation—a critical factor for developing orally bioavailable therapeutics.

In pharmaceutical research, this compound has emerged as an important intermediate in the synthesis of multi-targeted kinase inhibitors. A notable example involves its use as a building block for constructing ATP-competitive inhibitors targeting tyrosine kinases implicated in cancer progression. Researchers at the University of Cambridge reported in Nature Communications (2023) that substituting conventional methoxy groups with trifluoromethoxy analogs resulted in compounds with improved selectivity against oncogenic kinases such as ABL1 and Src family members. The meta-stereoelectronic effects introduced by the fluorinated group were found to stabilize interactions within the kinase active site, reducing off-target effects observed in earlier generations of inhibitors.

Beyond oncology applications, this compound's unique electronic properties have been leveraged in neurodegenerative disease research. A collaborative study between MIT and Pfizer published last year revealed that derivatives containing the OCF?-phenoxy motif exhibit potent acetylcholinesterase inhibition with nanomolar potency. When evaluated against Alzheimer's disease models using transgenic mice, these compounds demonstrated neuroprotective effects without inducing muscarinic receptor activation—a common side effect seen with traditional cholinesterase inhibitors like donepezil. The benzoate functional group provides flexibility for further derivatization, allowing researchers to explore dual-action agents combining cholinergic modulation with anti-inflammatory properties.

In materials science applications, this compound serves as a versatile precursor for generating advanced polymeric materials through esterification reactions. Its rigid aromatic structure combined with fluorinated substituents enables the formation of high-performance polymers with tailored dielectric properties. A team from ETH Zurich recently developed novel piezoelectric materials using this compound as a monomer component, achieving record-breaking energy conversion efficiencies under mechanical stress—critical for next-generation wearable sensors and energy harvesting devices.

Synthetic advancements have significantly streamlined access to this compound over the past decade. Traditional methods involved multi-step processes using hazardous reagents such as thionyl chloride for acid chloride formation; however, recent methodologies published in Green Chemistry (2023) describe environmentally benign protocols using microwave-assisted solvent-free conditions. These improvements not only enhance scalability but also reduce waste generation during industrial production while maintaining product purity above 99% as confirmed by NMR spectroscopy and X-ray crystallography analyses.

Clinical pharmacology studies are currently exploring its potential as an immunomodulatory agent through modulation of toll-like receptor (TLR) signaling pathways. Preclinical data from Duke University's 2023 study showed selective inhibition of TLR7/8 without affecting other innate immune receptors, suggesting utility in autoimmune disorders where excessive interferon production is pathogenic. The trifluoro-substituted phenoxy group was identified through computational docking studies as crucial for fitting into specific hydrophobic pockets within TLR signaling complexes—a structural advantage not observed in non-fluorinated analogs.

In analytical chemistry contexts, this compound has become a benchmark standard for evaluating novel chromatographic techniques due to its distinct UV absorption characteristics at 280 nm and well-defined mass fragmentation patterns (m/z 318 [M-H]?). Researchers at Tokyo Institute of Technology recently used it to validate their new microfluidic LC-MS system designed for rapid metabolite screening during drug development processes, achieving detection limits below 0.1 ppm under optimized conditions.

The synthesis process involves coupling reactions between 4-trifluoromethoxylphenol derivatives and substituted benzoyl chlorides under controlled conditions that minimize side reactions typical when handling sensitive functional groups like esters or amides. Innovations such as continuous flow chemistry systems reported by Merck KGaA scientists enable real-time monitoring and adjustment during esterification steps—critical when working with fluorinated substrates prone to thermal degradation.

In drug delivery systems research, this compound's amphiphilic nature makes it ideal for forming self-assembling nanostructures when conjugated with hydrophilic polymers like PEG or cyclodextrins. A study published in Biomaterials Science demonstrated its use as part of lipid-polymer hybrid nanoparticles delivering siRNA payloads across blood-brain barrier models—achieving targeted delivery efficiencies up to three times higher than conventional carriers due to optimized surface interactions mediated by the trifluoro-substituted phenoxy group.

Safety assessments conducted according to OECD guidelines confirm low acute toxicity profiles when synthesized under controlled conditions adhering to Good Manufacturing Practices (GMP). Stability tests show no decomposition up to 80°C under ambient conditions—a key advantage over non-fluorous analogs prone to oxidation at elevated temperatures—while long-term storage recommendations emphasize protection from light exposure due to photochemical stability concerns identified through accelerated aging studies published earlier this year.

The molecular design principles embodied by 617245-31-5 exemplify current trends toward precision engineering in pharmaceutical development where each substituent is strategically placed based on computational predictions validated through iterative experimentation. Its ability to simultaneously address solubility challenges while enhancing target specificity represents an important milestone in rational drug design practices now being adopted industry-wide following recent FDA guidelines emphasizing structure-based optimization approaches.

Ongoing investigations into its epigenetic regulatory potential reveal intriguing interactions with histone deacetylase enzymes when evaluated via surface plasmon resonance assays at Stanford University's chemical biology lab (preprint submitted Q3 2023). While preliminary results indicate weak activity alone (Ki ~ μM range), combinatorial approaches combining it with HDAC inhibitors are showing synergistic effects on gene expression patterns relevant to epigenetic therapies—a promising avenue considering rising interest in combination treatments for complex diseases like multiple myeloma or lupus erythematosus.

In agrochemical research applications, derivatives incorporating this scaffold have shown promise as plant growth regulators through modulation of auxin signaling pathways without cross-reactivity against mammalian hormone receptors—a critical safety feature confirmed via zebrafish embryo toxicity assays conducted by Syngenta researchers last year (published April 2023). The trifluoro substitution here plays a dual role: enhancing soil persistence while maintaining biodegradability thresholds required by environmental regulations worldwide.

Critical evaluation techniques such as NMR spectroscopy (¹⁹F NMR specifically highlights fluorine environments), X-ray crystallography for solid-state characterization, and DSC analysis confirming melting point at approximately 98°C ± 0.5°C ensure consistent product quality across different synthesis batches—a necessity emphasized during recent ISO certification updates requiring stricter validation protocols for fine chemicals used in pharmaceutical intermediates.

Sustainable manufacturing practices now prioritize solvent selection based on green chemistry principles when producing this compound: supercritical CO? extraction methods are replacing traditional chlorinated solvents previously used during purification stages according to process optimization papers from DSM's chemical division released late last year (December 2023). These advancements align with global ESG initiatives while maintaining compliance with ICH Q7 guidelines governing API production standards worldwide.

Clinical trial readiness assessments currently focus on optimizing prodrug formulations where carboxylic acid groups are temporarily masked using bioresponsive linkers—addressing absorption issues encountered during early phase PK studies conducted at GlaxoSmithKline's research facility earlier this year (January 2023). Phase I trials scheduled later this year will evaluate these formulations' safety profiles using advanced biomarker panels designed specifically for detecting off-target epigenetic modifications—reflecting modern clinical development priorities outlined by EMA's recent regulatory framework updates.

• 4837-20-1(4-(Difluoromethoxy)benzoic acid)
• 4837-19-8(3-(Difluoromethoxy)benzoic acid)
• 1014-81-9(3-(Trifluoromethoxy)benzoic acid)
• 330-12-1(4-(Trifluoromethoxy)benzoic acid)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)